The Stress Kinase p38α as a Target for Cancer Therapy

Ana Igea1, Angel R Nebreda2

  • 1Institute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain.

Cancer Research
|September 18, 2015
PubMed

Insights

The p38α protein kinase has a dual role in cancer, acting as both a tumor suppressor and a promoter of tumor growth and survival. Understanding its context-dependent functions is crucial for developing targeted cancer therapies.

Area of Science:

  • Cellular Biology
  • Molecular Oncology
  • Signal Transduction

Background:

  • p38α is a key protein kinase activated by stress and inflammatory signals.
  • It plays a role in regulating cell proliferation, differentiation, and apoptosis.
  • The precise role of p38α in cancer is complex and context-dependent.

Purpose of the Study:

  • To explore the dual role of p38α signaling in cancer.
  • To investigate its tumor-suppressor and pro-tumorigenic functions.
  • To highlight the therapeutic potential of p38α inhibition in cancer treatment.

Main Methods:

  • Literature review of studies on p38α in cancer.
  • Analysis of p38α's involvement in cell transformation, homeostasis, and apoptosis.
  • Examination of p38α's role in tumor cell survival and chemoresistance.

Main Results:

  • p38α can act as a tumor suppressor by preventing malignant transformation.
  • Conversely, p38α signaling can promote tumor cell survival and proliferation.
  • p38α activation contributes to tumor cell resistance to chemotherapy.

Conclusions:

  • p38α exhibits context-dependent functions in cancer, acting as both a tumor suppressor and promoter.
  • Inhibition of p38α may offer therapeutic benefits in certain cancer types.
  • Further research is needed to elucidate p38α's precise role in tumoral processes for effective therapeutic strategies.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.4K